Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI

The microflora-sparing properties of fidaxomicin were examined during the conduct of a randomized clinical trial comparing vancomycin 125 mg 4 times per day versus fidaxomicin 200 mg twice per day for 10 days as treatment of Clostridium difficile infection (CDI). Fecal samples were obtained from 89...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Louie, Thomas J., Cannon, Kris, Byrne, Brendan, Emery, Judy, Ward, Linda, Eyben, Melissa, Krulicki, Walter
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2012
Konular:
Supplement Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3388020/
https://ncbi.nlm.nih.gov/pubmed/22752862
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/cis338
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller